XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenon Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$35.08+1.59 (+4.75%)
Close on Oct 19, 2026
- Market cap
- $3.49B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.55 (−15.73%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Xenon Pharmaceuticals Inc. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Free cash flow was -$338.53M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$441.59M
TTM Q2 2026
Free cash flow
-$338.53M
TTM Q2 2026
EPS, diluted
-$4.74
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.49B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.81
- Dividend yield
- –
- Free cash flow yield
- -9.69%
Fundamentals
- Revenue
- $0
- Net income
- -$409.20M
- EPS, diluted
- -$4.74
- Free cash flow
- -$338.53M
- Book value per share
- $12.47
- Diluted shares
- 100M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$0-100.0% YoY
Operating income
-$441.59M
Net income
-$409.20M
EPS, diluted
-$4.74
Free cash flow
-$338.53M
Reported periodTrailing twelve months